Psychedelic Trials

Sub(acute) Profiling of 2C-B Versus Psilocybin
This interventional study, named PREDICT and conducted by Maastricht University, aims to comprehensively evaluate the acute and subacute effects of 2C-B compared to psilocybin and a placebo.
Status: Completed
Start date: 2021-08-04
Not Applicable
Blinded
18 participants
Interventional
A Trial of GH001 in Patients With Treatment-resistant Depression
This double-blind, placebo-controlled trial (n=80) investigates the safety and efficacy of GH001, containing mebufotenin (5-MeO-DMT), in treating treatment-resistant depression (TRD).
Status: Recruiting
Start date: 2023-05-24
Phase II
Blinded
80 participants
Interventional
Safety and Tolerability of DMT in Healthy Adults
This phase I, double-blind, randomized, placebo-controlled crossover trial (n=25) explores the acute and subacute effects of inhaled N,N-Dimethyltryptamine (DMT) in healthy adults.
Status: Completed
Start date: 2023-04-26
Phase I
Blinded
25 participants
Interventional
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This quadruple-masked, randomised, multi-centre Phase II study (n=225) investigates the efficacy and safety of a single intranasal dose of BPL-003, combined with psychological support, in patients with treatment-resistant depression (TRD).
Status: Recruiting
Start date: 2023-09-14
Phase II
Blinded
225 participants
Interventional
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
This open-label Phase II trial (n=12) is designed to assess the acute and subacute effects of inhaled N,N-Dimethyltryptamine (DMT) in patients with partial response in depression.
Status: Recruiting
Start date: 2023-10-09
Phase II
Open
12 participants
Interventional
Effects of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) administered by intramuscular injection on frequency oscillatory power bands in healthy adults
This single-blind, non-randomised trial (n=15) aims to explore the effects of intramuscularly administered 5-MeO-DMT (3-9 mg) on human brain activity and well-being indicators.
Status: Not yet recruiting
Start date: 2023-09-01
Phase I
Blinded
15 participants
Interventional
Interactions between 3,4-methylenedioxymethamphetamine (MDMA or ’ecstasy’) and Ä9-tetrahydrocannabinol (THC or ‘marihuana’) in humans
This completed interventional trial (n=16) investigated the interactions between MDMA and THC in humans.
Status: Completed
Start date: 2006-06-01
Blinded
16 participants
Interventional
A Double-Blind Randomised Controlled Trial of the Efficacy of Microdosing with Psilocybin to treat Moderate Depression
This double-blind randomised controlled trial (n=293) aims to evaluate the efficacy of microdosing with psilocybin as a treatment for moderate depression.
Status: Not yet recruiting
Start date: 2023-10-09
Phase II
Blinded
293 participants
Interventional
Investigating the safety, feasibility and acceptability of psilocybin-assisted psychotherapy in treatment resistant depression
This single-arm study (n=20) investigates the safety, feasibility, and acceptability of psilocybin-assisted psychotherapy in patients with treatment-resistant depression (TRD).
Status: Not yet recruiting
Start date: 2023-11-01
Phase I
Open
20 participants
Interventional
An open label study to investigate the safety and feasibility of delivering 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy to patients with posttraumatic stress disorder
This single-blind trial (n=15) will investigate the effects of intramuscularly administered 5-MeO-DMT on various aspects of human brain activity and well-being in healthy adults.
Status: Not yet recruiting
Start date: 2023-09-01
Phase I
Blinded
15 participants
Interventional
Effectiveness of Psychedelic Therapy for Treatment Resistant Depression (TRD)
This retrospective registration trial investigates the effectiveness of psychedelic therapy for Treatment Resistant Depression (TRD).
Status: Recruiting
Start date: 2023-12-04
Phase IV
Open
30 participants
Interventional
Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)
This interventional trial (n=30) will assess the efficacy and safety of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD) using MDMA.
Status: Recruiting
Start date: 2023-12-04
Phase IV
Open
30 participants
Interventional
Ketamine versus Ketamine plus Behavioural Activation Therapy for Adults with Treatment Resistant Depression
This interventional trial (n=60) will assess the efficacy and safety of Ketamine-Assisted Psychotherapy (KAP) involving Behavioural Activation Therapy (BAT) in adults with Treatment-Resistant Major Depressive Disorder (TRD).
Status: Not yet recruiting
Start date: 2023-10-02
Not Applicable
Blinded
60 participants
Interventional
A clinical trial to assess safety and efficacy of psilocybin-assisted psychotherapy for treatment-resistant anorexia nervosa in adults
This single-blind, phase II trial (n=30) will assess the safety and efficacy of psilocybin-assisted psychotherapy for treatment-resistant anorexia nervosa in adults.
Status: Not yet recruiting
Start date: 2023-07-01
Phase II
Blinded
30 participants
Interventional
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)
This open-label pilot trial (n=20) assesses the tolerability and feasibility of LSD microdosing in patients with major depressive disorder (MDD).
Status: Recruiting
Start date: 2023-08-14
Phase II
Open
20 participants
Interventional
Efficacy and safety of two versus three high dose psilocybin-assisted therapy sessions in comparison to a placebo for treatment resistant major depressive disorder (TR-MDD): A double blind, 3-arm Phase 2b randomised controlled trial
This double-blind, 3-arm Phase IIb randomised controlled trial (n=160) will investigate the efficacy and safety of two versus three high dose psilocybin-assisted therapy sessions compared to a placebo for treatment-resistant major depressive disorder (TR-MDD).
Status: Recruiting
Start date: 2023-08-14
Phase II
Blinded
160 participants
Interventional
The role of 5-HT2 and 5-HT1A receptors in 3,4-methylenedioxymethamphetamine (MDMA) induced memory impairment and impulsivity.
This interventional crossover trial (n=18) aimed to investigate the role of 5-HT2 and 5-HT1A receptors in MDMA-induced memory impairment and impulsivity.
Status: Completed
Start date: 2010-03-01
Open
18 participants
Interventional
Can memantine prevent memory impairment induced by MDMA in humans.
This double-blind, placebo-controlled crossover trial (n=16) investigates whether pretreatment with memantine can prevent the memory impairment typically caused by MDMA in recreational users.
Status: Completed
Start date: 2011-04-01
Not Applicable
Blinded
16 participants
Interventional
MDMA, Cortisol and Memory
This interventional trial (n=60) investigates the impact of MDMA on memory and cortisol levels in ecstasy users.
Status: Unknown status
Start date: 2008-11-01
Not Applicable
Blinded
60 participants
Interventional
Come closer: a neurobiological analysis of the prosocial effects of MDMA
This double-blind, placebo-controlled crossover trial (n=24) conducted by Maastricht University explores the prosocial effects of MDMA, oxytocin, and their interaction.
Status: Completed
Start date: 2011-06-14
Not Applicable
Blinded
24 participants
Interventional
Evaluating the Positioning of Esketamine Treatment (PoET) for symptom management in adults with major depressive disorder
This uncontrolled, single-arm, naturalistic study (n=162) aims to evaluate the positioning of Esketamine Treatment (PoET) for symptom management in adults with major depressive disorder (MDD).
Status: Not yet recruiting
Start date: 2023-10-17
Phase IV
Open
162 participants
Interventional
The role of the 5-HT2a receptor in MDMA-induced effects on social cognition and prosocial behaviour
This double-blind, placebo-controlled crossover trial (n=24) investigates the role of the 5-HT2a receptor in MDMA-induced effects on social behaviour.
Status: Completed
Start date: 2013-01-23
Not Applicable
Blinded
24 participants
Interventional
Effects of alcohol (0.5 %0) and MDMA (100 mg) on (simulated) driving performance, driving related performance and traffic safety
This crossover study (n=20) aimed to assess the effects of a single dose of MDMA (100 mg) and/or alcohol (0.5%) on simulated driving performance.
Status: Completed
Start date: 2010-04-05
Not Applicable
Open
20 participants
Interventional
Effect of SSRIs on Response to Psilocybin Therapy
This open-label, single-arm trial (n=30) aimed to evaluate the effect of length of time on selective serotonin reuptake inhibitors (SSRIs) on the response to psilocybin-assisted therapy in individuals with mild-moderate Major Depressive Disorder (MDD).
Status: Withdrawn
Start date: 2023-01-01
Phase II
Open
0 participants
Interventional
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD (MDMA-bCBCT)
This open-label trial (n=16) will examine the preliminary effectiveness of MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy (MDMA-bCBCT) in improving chronic PTSD and relationship functioning in veterans and their intimate partners within the VA San Diego Healthcare System.
Status: Recruiting
Start date: 2023-10-06
Phase III
Open
16 participants
Interventional
Dose-finding PKPD Trial for RE02 in Healthy Subjects
This double-blind, randomized, dose-response trial (n=15) aims to assess the pharmacokinetic and pharmacodynamic profiles of RE02, a psychedelic drug, in healthy subjects.
Status: Recruiting
Start date: 2023-11-20
Phase I
Blinded
15 participants
Interventional
Functional, cognitive and behavioural effects of 5-MeO-DMT administered by intramuscular injection
This single-blind study aims to investigate the effects of intramuscularly (IM) administered 5-MeO-DMT on various aspects of human brain activity and well-being in healthy adults.
Status: Not yet recruiting
Start date: 2023-09-01
Phase I
Blinded
15 participants
Interventional
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)
This randomised, controlled clinical trial (n=128) aims to investigate whether a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2024-01-01
Phase II
Blinded
128 participants
Interventional
Psilocybin in Cancer Pain Study
This open-label, single-group assignment trial (n=15) aims to assess the feasibility, safety, and preliminary efficacy of psilocybin-assisted therapy for opioid-refractory pain in patients with advanced cancer.
Status: Not yet recruiting
Start date: 2024-01-01
Phase II
Open
15 participants
Interventional
PARTING: Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief
This single-arm, open-label trial (n=15) aims to assess the feasibility, acceptability, and safety of Psilocybin-Assisted Supportive Psychotherapy in treating prolonged grief disorder in bereaved cancer carers.
Status: Recruiting
Start date: 2023-11-13
Phase II
Open
15 participants
Interventional

Find Psychedelic Trials

Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.

The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.